{
    "clinical_study": {
        "@rank": "132917", 
        "arm_group": {
            "arm_group_label": "Busulfan", 
            "arm_group_type": "Experimental", 
            "description": "Drug: Busulfan First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the outcome of hematopoietic stem cell transplantation using targeted busulfan,\n      fludarabine, etoposide conditioning regimen in childhood and adolescent ALL."
        }, 
        "brief_title": "Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL.", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Lymphoblastic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Busulfan is a highly toxic drug with narrow therapeutic window used for the conditioning of\n      hematopoietic stem cell transplantation. High exposure is associated with systemic toxicity\n      such as veno-occlusive disease (VOD) and underexposure is associated with graft failure or\n      relapse. In this study the investigators plan to improve the outcome of hematopoietic stem\n      cell transplantation by using optimal busulfan dose through pharmacokinetic study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients who are diagnosed as ALL.\n\n          2. Patients who need hematopoietic stem cell transplantation\n\n          3. Age: up to 21 years\n\n          4. Performance status: ECOG 0-2.\n\n          5. Patients must be free of significant functional deficits in major organs, but the\n             following eligibility criteria may be modified in individual cases. 1. Heart: a\n             shortening fraction > 30% and ejection fraction > 45%. 2. Liver: total bilirubin < 2\n             \u00d7 upper limit of normal; ALT < 3 \u00d7 upper limit of normal. 3. Kidney: creatinine <2 \u00d7\n             normal or a creatinine clearance (GFR) > 60 ml/min/1.73m2.\n\n          6. Patients must lack any active viral infections or active fungal infection.\n\n          7. Appropriate donor is available: Matched in 6/6 of A, B, DR loci.\n\n          8. Patients (or one of parents if patients age < 19) should sign informed consent.\n\n        Exclusion Criteria:\n\n          1. Pregnant or nursing women.\n\n          2. Malignant or nonmalignant illness that is uncontrolled or whose control may be\n             jeopardized by complications of study therapy.\n\n          3. Psychiatric disorder that would preclude compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047578", 
            "org_study_id": "SNUCH_ALL_BuFluVP"
        }, 
        "intervention": {
            "arm_group_label": "Busulfan", 
            "description": "First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study", 
            "intervention_name": "Busulfan", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Busulfan", 
                "Fludarabine", 
                "Etoposide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "hematopoietic stem cell transplantation", 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "contact": {
                "email": "kanghj@snu.ac.kr", 
                "last_name": "Hyoung Jin Kang, MD, PhD", 
                "phone": "82 2 2072 3304"
            }, 
            "contact_backup": {
                "email": "agnesjw@hanmail.net", 
                "last_name": "Ji Won Lee, MD", 
                "phone": "82 2 2072 4192"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Daehangno, Jongno-gu"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Childhood and Adolescent Acute Lymphoblastic Leukemia", 
        "other_outcome": [
            {
                "description": "To evaluate toxicities associated with hematopoietic stem cell transplantation. Toxicities will be assessed with number of participants.", 
                "measure": "Toxicities associated with hematopoietic stem cell transplantation", 
                "safety_issue": "No", 
                "time_frame": "1, 3, 6 and 12 months after transplantation"
            }, 
            {
                "description": "To evaluate acute GVHD", 
                "measure": "Acute GVHD", 
                "safety_issue": "No", 
                "time_frame": "1, 3, 6 and 12 months after transplantation"
            }, 
            {
                "description": "To evaluate chronic GVHD", 
                "measure": "Chronic GVHD", 
                "safety_issue": "No", 
                "time_frame": "1, 3, 6 and 12 months after transplantation"
            }, 
            {
                "description": "To evaluate treatment related mortality", 
                "measure": "Treatment related mortality", 
                "safety_issue": "No", 
                "time_frame": "1, 3, 6 and 12 months after transplantation"
            }, 
            {
                "description": "To evaluate relapse rate", 
                "measure": "Relapse rate", 
                "safety_issue": "No", 
                "time_frame": "1, 3, 6 and 12 months after transplantation"
            }
        ], 
        "overall_contact": {
            "email": "kanghj@snu.ac.kr", 
            "last_name": "Hyoung Jin Kang, MD, PhD", 
            "phone": "82 2 2072 3304"
        }, 
        "overall_contact_backup": {
            "email": "agnesjw@hanmail.net", 
            "last_name": "Ji Won Lee, MD", 
            "phone": "82 2 2072 4192"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Hyoung Jin Kang, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate 1-year event free survival after hematopoietic stem cell transplantation.", 
            "measure": "1-year event free survival after hematopoietic stem cell transplantation.", 
            "safety_issue": "Yes", 
            "time_frame": "at 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047578"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate engraftment rate", 
            "measure": "Engraftment rate", 
            "safety_issue": "No", 
            "time_frame": "1, 3, 6 and 12 months after transplantation"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}